Galunisertib is a selective inhibitor of TGF-β receptor type I (ALK5), capable of blocking TGF-β signaling, inhibiting tumor growth and metastasis, and demonstrating potential in the treatment of malignant tumors. Here, TGFB1 is linked to neoplasm.